From economics to health outcomes: Delving into the significance of reduced insulin prices
DOI:
https://doi.org/10.7196/SAMJ.2024.v114i8.2014Keywords:
Diabetes management, Insulin affordability, Essential Medicine List, Healthcare disparitiesAbstract
The recent substantial price reductions in insulin therapy by major manufacturers prompt an examination of their impact on South Africa (SA)’s healthcare. While Eli Lilly, Novo Nordisk, and Sanofi cut prices on long-acting basal insulin, among others, significantly, these insulins are not on SA’s Essential Medicines List (EML) for primary healthcare. With a high prevalence of diabetes, especially pre-diabetes, in the country, the EML’s neglect of newer long-acting insulin treatments hampers effective disease management. Despite efforts by the public and private sectors, insulin therapy initiation is delayed, impacting long-term outcomes. The introduction of smart insulin pens adds a technological dimension, but concerns persist about equitable access. Urging policy-makers to re-evaluate guidelines and decolonise the EML, the article emphasises enhancing patient quality of life and reducing the disease burden.
References
Suran M. All 3 major insulin manufacturers are cutting their prices—here’s what the news means for patients with diabetes. JAMA 2023;329(16):1337-1339. https://doi.org/10.1001/jama.2022.11688
National Department of Health, South Africa. PHC Standard Treatment Guidelines and Essential Medicines List. Pretoria: NDoH, 2024. https://knowledgehub.health.gov.za/elibrary/primary-healthcare- phc-standard-treatment-guidelines-stgs-and-essential-medicines-list-eml (accessed 15 February 2024).
InternationalDiabetesFederation.Diabetesaroundtheworldin2021.IDFDiabetesAtlas10thed.,2021. https://idf.org/about-diabetes/facts-figures/ (accessed 16 February2024).
InternationalDiabetesFederation.SouthAfricaDiabetesreport2000-2045.IDFDiabetesAtlas10thed., 2021. https://diabetesatlas.org/data/en/country/185/za.html (accessed 16 February 2024).
Pheiffer C, Pillay-van Wyk V, Turawa E, Levitt N, Kengne AP, Bradshaw D. Prevalence of type 2 diabetes in South Africa: A systematic review and meta-analysis. Int J Env Res Public Health 2021;18(11):5868. https://doi.org/10.3390/ijerph18115868
Grundlingh N, Zewotir TT, Roberts DJ, Manda S. Assessment of prevalence and risk factors of diabetes and pre-diabetes in South Africa. J Health Popul Nutr 2022;41(1):1-12. https://doi.org/10.1186/s41043- 022-00281-2
Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49(12):2142-2148. http:// diabetesjournals.org/diabetes/article-pdf/49/12/2142/365740/11118018.pdf (accessed 17 February 2024).
Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharmaceutical Res 2004;21:1498-1504.
Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: A 26-week, randomised, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. Diabetes Care 2013;36(9):2536- 2542. https://doi.org/10.2337/dc12-2329. Clinical trial reg. no. NCT01068665 clinicaltrials.gov
OwensDR.Clinicalevidencefortheearlierinitiationofinsulintherapyintype2diabetes.DiabetesTech Therapeutics 2013;15(9):776-785. https://doi.org/10.1089/dia.2013.0081
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41(12):2669-2701. https://doi.org/10.2337/dci18-0033
Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial. Lancet 2008;371(9626):1753-1760. https://doi.org/10.1016/S0140-6736(08)60762-X
Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care 2004;27(11):2597-2602.
Kong MF, Bickerton A. Insulin should be prescribed at the outset of diagnosis of type 2 diabetes. Practical Diabetes Int 2011;28(2):85-87. https://doi.org/10.1002/pdi.1564
Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013;1(1):28-34. https://doi. org/10.1016/S2213-8587(13)70006-8
HanefeldM,FleischmannH,SiegmundT,SeufertJ.Rationalefortimelyinsulintherapyintype2diabetes within the framework of individualised treatment: 2020 update. Diabetes Ther 2020;11(8):1645-1666. https://doi.org/10.1007/s13300-020-00855-5
SouthAfrica.MedicalSchemesActNo.131of1998.
PalumboPJ.Thecaseforinsulintreatmentearlyintype2diabetes.ClevelandClinJMed2004;71(5):385-408. 19. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association
with outcomes: A data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018;6(5):361-
https://doi.org/10.1016/S2213-8587(18)30051-2
Fick M. Novo Nordisk contracts Aspen to produce insulin for Africa. BusinessDay, 19 September 2023.
https://www.businesslive.co.za/bd/companies/healthcare/2023-09-19-novo-nordisk-contracts-aspen-to- produce-insulin-for-africa/ (accessed 16 February 2024).
Downloads
Published
Issue
Section
License
Copyright (c) 2024 M Leuschner, M Strydom, V Steenkamp
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
